Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Triple-Negative Breast Cancer
Advertisement
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC.
Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.